For the first time, thousands of patients with generalized myasthenia gravis who test negative for the most common antibody markers now have access to Vyvgart, a targeted treatment previously available only to a narrower group. The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and its subcutaneous formulation, Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), to treat all adult patients with generalized myasthenia gravis, regardless of antibody type—a shift that closes a long-standing gap in care.
Myasthenia gravis is a rare autoimmune disease in which the body produces antibodies that disrupt communication between muscles and nerves, causing severe weakness and fatigue. Until now, most treatment options focused on patients who tested positive for anti-AChR antibodies, leaving those with anti-MuSK antibodies, anti-LRP4 antibodies, or no detectable antibodies largely without targeted therapies. This expanded approval recognizes that patients across all four categories—anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative—can benefit from efgartigimod, a therapy designed to reduce disease-causing antibodies.
The decision rests on the Phase III ADAPT SERON trial, which tracked how Vyvgart performed across different serotypes. Participants showed clinically meaningful improvements in multiple quality-of-life measures, including speech, vision, physical function, and swallowing—the everyday abilities that myasthenia gravis disrupts most severely. At the four-week mark, Vyvgart achieved statistically significant improvement in the Myasthenia Gravis Activities of Daily Living total score, the study's primary measure. The drug was well tolerated across all serotypes, maintaining the safety profile established in earlier trials.
Argenx, the biopharmaceutical company behind Vyvgart, submitted the supplemental Biologics License Application to bring this expanded indication to patients. The approval matters because it reflects a growing recognition that disease mechanisms in myasthenia gravis vary by antibody status—and that one targeted therapy can work across that spectrum.
"For too long, gMG patients who do not have detectable AChR-Ab have been left behind," said Allison Foss, executive director of the Myasthenia Gravis Association. "This approval validates that gMG patients without AChR-Ab can benefit from a targeted treatment, bringing a sense of hope to thousands in our community." Those words carry weight: before this expansion, antibody-negative and anti-MuSK patients faced severely limited options, often managed with older immunosuppressants or plasma exchange—treatments less precise and more burdensome than a therapy engineered for their specific disease.
For patients who have spent years managing symptoms with treatments designed for other conditions, or navigating through trial and error, this approval signals a turning point. It demonstrates how deeper understanding of rare disease biology can translate into expanded access and better outcomes. The hope now extends beyond the AChR-positive patients who had already benefited from Vyvgart—it reaches the thousands living with antibody variants, finally offering them a treatment pathway that acknowledges and addresses their form of the disease.